Temotero

Temotero

temozolomide

Manufacturer:

Hetero Labs

Distributor:

Camber
Concise Prescribing Info
Contents
Temozolomide
Indications/Uses
Newly-diagnosed glioblastoma multiforme concomitantly w/ radiotherapy in adults. Malignant glioma eg, glioblastoma multiforme or anaplastic astrocytoma in adults, adolescents & childn >3 yr.
Dosage/Direction for Use
Concomitant phase: 75 mg/m2 orally for 42 days concomitant w/ focal radiotherapy. Monotherapy phase: 150 mg once daily for 5 days followed by 23 days w/o treatment for cycle 1. Increased to 200 mg/m2 in cycle 2.
Administration
Should be taken on an empty stomach: Take in the fasting state. Swallow whole w/ a glass of water & must not be opened or chewed.
Contraindications
Hypersensitivity to dacarbazine. Severe myelosuppression.
Special Precautions
Pneumocystis carinii pneumonia. Nausea & vomiting. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Childn <3 yr. Elderly.
Adverse Reactions
Anorexia; convulsions, headache; constipation, nausea, vomiting; rash, alopecia; fatigue; neutropenia or lymphopenia, thrombocytopenia.
Drug Interactions
Decreased clearance w/ valproic acid. Increased myelosuppression w/ myelosuppressive agents.
ATC Classification
L01AX03 - temozolomide ; Belongs to the class of other alkylating agents. Used in the treatment of cancer.
Presentation/Packing
Form
Temotero cap 100 mg
Packing/Price
5's
Form
Temotero cap 20 mg
Packing/Price
5's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in